India's triumphs in the battle against TB
Authors - Dr K Madan Gopal, advisor, PHA NHSRC, Dr Suneela Garg, chair, programme advisory committee, NIHFW MoHFW, KS Uplabdh Gopal, health care professional.
Stay updated with breaking news from Interface Agency. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Authors - Dr K Madan Gopal, advisor, PHA NHSRC, Dr Suneela Garg, chair, programme advisory committee, NIHFW MoHFW, KS Uplabdh Gopal, health care professional.
The Department of Biotechnology (DBT) has announced that the Omicron-specific mRNA-based Booster vaccine developed using the indigenous platform technology by Gennova Biopharmaceuticals Ltd. and supported under the Mission COVID Suraksha, implemented by Biotechnology Industry Research Assistance Council (BIRAC), has got a nod from the office of the Drug Control General of India (DCGI) for Emergency Use Authorization (EUA).
New Delhi: Drug Controller General Of India (DCGI) gave a restricted emergency use approval to the Zydus Cadila’s ‘Virafin’ for treating the patients showing moderate COVID-19 symptoms. Virafin is a pegylated interferon alpha-2b(PegIFN), which when s
Share Vaccine Discovery Programme supported by the Department of Biotechnology, Govt. of India under the Mission COVID Suraksha- The Indian COVID-19 Vaccine Development Mission, implemented by BIRAC, moves into clinical trials The Department of Biotechnology (DBT), Ministry of Science & Technologyhas announced that it has approved additional funding towards clinical studies of India’s’first of its kind’ mRNA-based COVID-19 vaccine – HGCO19, developed by Pune-based biotechnology company Gennova Biopharmaceuticals Ltd. This funding has been awarded under the’Mission COVID Suraksha- Th...